Hyperlipidemia refers to abnormal elevation of lipids and/or lipoprotein levels. Risks associated with this condition include stroke, peripheral vascular disease, atherosclerosis, diabetes, obesity, hypertension, and cardiovascular diseases. Drugs which are used to treat hyperlipidemia either accelerate the elimination of lipoproteins from the body or decrease production of lipoproteins. These drugs not only lower the unwanted cholesterol levels but are vital for lowering the risk of   heart attacks or strokes. Primary causes of this disease include sedentary lifestyle, increase in alcohol consumption, and changes in dietary pattern. Additionally, increase in consumption of red meats, fried & processed foods, sugar, and rich foods increase blood cholesterol levels.

The global hyperlipidemia prescription drugs market is estimated to expand substantially due to rise in susceptibility to heart diseases associated with the aging population. Other factors such as patent expiration and availability of funding, undertaking of health awareness programs by health care centers, high incidence rate of cardiovascular diseases, and rising awareness among people about reducing the harmful cholesterol levels to control heart diseases are projected to drive the market during the forecast period. A large number of hyperlipidemia drugs are in phase III of clinical trials for their assessment in providing clinical benefits and long-term safety records.

The global hyperlipidemia prescription drugs market can be segmented based on drug class, end-user, and region. In terms of drug class, the hyperlipidemia prescription drugs market can be classified into HMG COA reductase inhibitors, fibric acid derivatives, nicotinic acids, bile acid sequestrating agents, cholesterol absorption inhibitors, and others. Based on end-user, the hyperlipidemia prescription drugs market can be categorized into hospitals and clinics. In terms of region, the global hyperlipidemia prescription drugs market can be divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The hyperlipidemia prescription drugs market in each region is sub-divided into specific countries such as the U.S., Canada, Germany, the U.K., Brazil, China, India, Japan, and GCC countries. North America dominates the global hyperlipidemia prescription drugs market, followed by Europe due to high prevalence of diseases associated with elevated levels of lipoproteins and growing baby boomer population. According to the Centers for Disease Control and Prevention (CDC), every year about 630,000 people succumb to heart diseases in the U.S. Annually 1,055,000 people in the U.S. are victims of heart attacks. Of these cases 720,000 are a first heart attack and 335,000 happen to people who have already had a first heart attack. Asia Pacific is estimated to be a highly attractive region of the market during the forecast period due to highly developed health care infrastructure, and higher adoption rate of technologically advanced therapeutic products. Additionally, rise in aging population and increase in awareness about heart disease are some factors fueling the hyperlipidemia prescription drugs market.

Key players operating in the global hyperlipidemia prescription drugs market include Amgen, Inc., Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals Limited, Isis Pharmaceuticals, Inc., Merck & Co., Inc., Dr. Reddy\'s Laboratories Limited, Immuron Limited, Esperion Therapeutics, Inc., Pfizer, Inc., and Formac Pharmaceuticals N.V.  Major players actively engage in various growth strategies such as collaborations, partnerships, agreements, and product launches to gain a competitive advantage in the market.

This intelligence report by TMR is the outcome of intense study and rigorous assessment of various dynamics shaping the growth of the market. TMR nurtures a close-knit team of analysts, strategists, and industry experts who offer clients tools, methodologies, and frameworks to make smarter decisions. Our objective, insights, and actionable analytics provide CXOs and executives to advance their mission-critical priorities with confidence.

The scrutiny of the various forces impacting the dynamics of the market, and key and associated industries, guides enterprises in understanding various consumer propositions. Our clients leverage these insights and perspectives to enhance customer experience in the fast-paced business environment.

All our insights and perspectives are broadly based on 4 Pillars or Stages: ASBC-S, which offer an elaborate and customizable framework for the success of an organization. The essence and the roles of these in organizational successes are highlighted below:

  • Agenda for CXOs: TMR, through the study, sets the tone for agendas that are pertinent to CEOs, CFOs, CIOs, and other CXO executives of businesses operating in the market. The perspectives help our clients to bridge the gap between agenda and action plan. TMR strives to offer guidance to CXOs to undertake mission-critical activities empowered by various business analysis tools, and boost the performance of the organizations. The perspectives guide you to decide on your own marketing mix that align well with the policies, visions, and mission.
  • Strategic Frameworks: The study offers how organizations are setting both short-term and long-term strategic plans. Our team of experts collaborate and communicate with you to understand these to make your organizations sustainable and resilient during tough times. The insights help them decide sustainable competitive advantage for each business units.
  • Benchmarking for Deciding Target Markets and Brand Positioning: The assessments in the study provides a scrutiny of marketing channels and marketing mix. Our various teams work synergistically with you to help identify your actual and potential direct, indirect, and budget competition areas. Additionally, the study helps you decide most effective budgets for various processes and promotional activities. Furthermore, the study guides you to set benchmarks for integrating people and processes with the 4Ps of marketing. Eventually, this will empower you to find out unique propositioning strategies and niches.
  • Business Composability for Sustainability (C-S): Constant strategy planning for sustainability characterizing our C-S framework in the report has become more relevant than before in the face of disruptions caused by pandemics, recessions, boom and bust cycles, and changing geopolitical scenario. The TMR study offers a high level of customization to help you achieve business composability. Composable enterprises are increasingly gaining the attention of CXOs in order to help them combat market volatility. Our analysts and industry experts help you wade through such uncertainties and guide you to become a smart sustainable business in entirety.

The study presents scrutiny of region-specific consumer and technology trends, including the most recent industry dynamics. These broadly cover but not limited to

  • North America, South America, and the Americas
  • Asia Pacific and Japan
  • Europe
  • Latin America
  • Middle East and Africa

The study offers data-driven insights and guidance of several aspects. Some of the more notable questions are:

  • What are the major recent trends that can influence the product life cycle and the RoI?
  • Which regulatory trends shape corporate-level, business-level, and functional-level strategies?
  • Which micromarketing initiatives of leading players will bring in investments?
  • What can be the best framework and tools for PESTLE analysis?
  • Which regions will witness rise in new opportunities?
  • Which are the game-changing technologies being used to capture new revenue streams in the near future?
  • Which operational and tactical frameworks are being adopted by various players in gaining customer loyalty?
  • What is the current and expected intensity of competition the market in the near future?

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Disclaimer: This market research study is an ongoing effort and extreme care has been taken to maintain the highest levels of accuracy at all stages. However, in the light of the rapidly evolving business dynamics, some region-specific or other segment-specific changes may take time to be part of the study.

Enquiry Before Buying

TMR offers Enquiry Before Buying that help clients to get information on their business scenario required where syndicated solutions are not enough.

Enquiry Before Buying

Hyperlipidemia Prescription Drugs Market